{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:04:49Z","timestamp":1781712289837,"version":"3.54.5"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009431","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T02:41:16Z","timestamp":1513910476000},"page":"e9431","source":"Crossref","is-referenced-by-count":36,"title":["Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer"],"prefix":"10.1097","volume":"96","author":[{"given":"Zhenping","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-159-20210226","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J"},{"key":"R2-159-20210226","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R3-159-20210226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R4-159-20210226","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cncr.29769","article-title":"Immunotherapy in hepatocellular carcinoma: primed to make a difference?","volume":"122","author":"Harding","year":"2016","journal-title":"Cancer"},{"key":"R5-159-20210226","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R6-159-20210226","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R7-159-20210226","first-page":"ii","article-title":"A mini-review for cancer immunotherapy: molecular understanding of PD-1\/PD-L1 pathway and translational blockade of immune checkpoints","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R8-159-20210226","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-159-20210226","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R10-159-20210226","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: a review in advanced melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"R11-159-20210226","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-159-20210226","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:49:24Z","timestamp":1620960564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712220-00159"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009431","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}